Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region

by Colby S. Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs, Shweta Vadhavkar, René Bruno, Benjamin Wu
Published 2021-06-01

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

by Shukui Qin, Zhenggang Ren, Yin-Hsun Feng, Thomas Yau, Baocheng Wang, Haitao Zhao, Yuxian Bai, Shanzhi Gu, Lindong Li, Sairy Hernandez, Derek-Zhen Xu, Sohail Mulla, Yifan Wang, Hui Shao, Ann Lii Cheng
Published 2021-04-01